Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag ADR (OP:BAYRY)

10.40 +10.40 (+1039900.00%)

Streaming Delayed Price Updated: 3:59 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >

Earnings Review: Bayer To Make Strategic Changes After Q3 Results ↗

November 08, 2023

The latest financial statements from Bayer Group show a year-over-year decline in several key areas, painting a stark picture of the company’s fiscal health.

Via Talk Markets

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗

November 01, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving ↗

September 27, 2023

Investors tend to closely watch which Cathie Wood stocks are bought and sold as she has history of generating big returns in her ETFs

Via InvestorPlace

AI To Revolutionize Clinical Trials And Diagnostics ↗

September 22, 2023

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...

Via Benzinga

Topics Artificial Intelligence

Daily Stock Analysis: Bayer AG - May '23 Update ↗

May 17, 2023

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as over the counter products.

Via Talk Markets

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch ↗

September 12, 2023

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for...

Via Benzinga

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗

August 28, 2023

Reuters

Via Benzinga

German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗

August 28, 2023

Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields...

Via Benzinga

FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗

August 21, 2023

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

Via Benzinga

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? ↗

August 08, 2023

Tiziana Life Sciences, Inc.

Via Benzinga

Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema ↗

July 31, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,...

Via Benzinga

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗

July 17, 2023

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in...

Via Benzinga

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗

June 29, 2023

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...

Via Benzinga

Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study ↗

June 28, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced

Via Benzinga

Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters ↗

June 28, 2023

Via Benzinga

Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗

June 27, 2023

The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday.

Via Investor's Business Daily

Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst ↗

June 23, 2023

Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a

Via Benzinga

Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts ↗

June 27, 2023

Via Benzinga

There’s Only One Way To Beat The Market ↗

June 12, 2023

The way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. Today, I want to show you how savvy stock pickers can profit from...

Via Talk Markets

Perrigo Picks Former Bayer Executive As New CEO ↗

June 08, 2023

Perrigo Co PLC (NYSE: PRGO) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors,

Via Benzinga

Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries ↗

April 27, 2023

Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present...

Via Talk Markets

Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗

April 24, 2023

Via Benzinga

After That Big Merger, What Happened? ↗

April 15, 2023

There are often substantial controversies over whether a merger should be allowed to happen, but then relatively little follow-up after the event.

Via Talk Markets

InvestorNewsBreaks – ROTH MKM’s Agribusiness Investment Banking Group Serves as Sellside Advisor for Three M&A Transactions

April 11, 2023

Via Investor Brand Network

Topics Derivatives

Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories ↗

April 04, 2023

Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning

Via Benzinga

US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities ↗

April 04, 2023

Via Benzinga

Evogene Offers An Excellent Risk/Reward Ratio ↗

March 21, 2023

We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their...

Via Talk Markets

Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B ↗

March 10, 2023

Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years.

Via Benzinga

EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗

February 15, 2023

Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.